18. Subsequent Event

Acquisition of Riverpoint Medical

On June 8, 2026, the Company entered into a definitive agreement to acquire Riverpoint Medical, a category leader in high-growth minimally invasive surgical consumables. On July 23, 2026, the Company completed the acquisition of all of the issued and outstanding limited liability company interests of the parent entity of Riverpoint Medical for total upfront cash consideration of $1.2 billion, subject to customary closing and net working capital adjustments. In addition, the agreement provides for a milestone payment of $250.0 million payable on or before January 8, 2027.

The Company funded the purchase price through $616.0 million of borrowings under the revolving credit facility and delayed draw term loan facility of its Fourth Amended and Restated Credit Agreement, with the remainder funded from cash on hand.

The Riverpoint Medical acquisition will be included in the Medical Solutions reportable segment. Information required by ASC 805-10, “Business Combinations,” is not disclosed herein as the Company is in the process of completing its purchase accounting evaluation, including purchase price allocation and other related disclosures.